About Dr. Ajay Bapna
Dr. Ajay Bapna is a highly experienced and respected Medical Oncologist. With over 29 years of dedicated practice in oncology, Dr. Bapna played a pivotal role in establishing the Medical Oncology department at BMCHRC. He holds an MD in Internal Medicine and specialised further with a DM in Medical Oncology from the renowned Tata Memorial Hospital, Mumbai. Dr. Bapna’s expertise encompasses a wide range of cancer treatments, with special interests in immunotherapy, targeted therapy, and chemotherapy, alongside Paediatric Oncology and Haematology. He is known for his meticulous approach to diagnosis and his empathetic care for patients. An active member of key oncology societies like ASCO and ISMPO, Dr. Bapna remains at the forefront of cancer research and treatment advancements.
Qualifications & Credentials
- MBBS: Sawai Man Singh Medical College, Jaipur
- MD (Internal Medicine): Sawai Man Singh Medical College, Jaipur
- DM (Medical Oncology): Tata Memorial Center / Tata Memorial Hospital, Mumbai
- Specialised Oncology training at Tata Memorial Hospital, Mumbai
Areas of Expertise
- Lung Cancer
- Breast Cancer
- Head and Neck Cancer
- Ovarian Cancer & other Gynaecological Cancers
- Gastrointestinal Cancers (Oesophageal, Stomach, Small Intestine, Colon)
- Haematological Malignancies (Leukaemia, Lymphoma, Multiple Myeloma)
- Genitourinary Cancers
- Adrenal Gland Cancer
- Liver Cancer
- Paediatric Cancers
- Thyroid Cancer
- Mouth Cancer
- Medical Oncology
- Paediatric Oncology
- Haematology
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Hormonal Therapy
List of Disease and Treatment for which Dr. Ajay Bapna can be consulted
Professional Experience
- Director & HOD, Department of Medical Oncology – Bhagwan Mahaveer Cancer Hospital & Research Centre (BMCHRC), Jaipur (Present)
- Actively involved in research work and various workshops within Medical Oncology.
- Authored and co-authored numerous papers published in national and international journals.
- Participates in clinical research and stays updated through professional memberships.
- Founding member and establisher of the Department of Medical Oncology at BMCHRC (1998).
Awards & Recognitions
- Dainik Bhaskar Healthcare Award 2021 (Excellence in Oncology, Jaipur)
- Member: Indian Cooperative Oncology Network (ICON)
- Member: Indian Society of Medical and Paediatric Oncology (ISMPO)
- Member: American Society of Clinical Oncology (ASCO).
Research & Publications
- Genetic Counselling, Testing, and Management of Hereditary Breast and Ovarian Cancer Syndrome in India: Updated Expert Consensus Recommendations from Indian Society of Medical and Pediatric Oncology. Indian Journal of Medical and Paediatric Oncology (March 2025 – Note: Future date as per source)
- Real-World Evidence of the Impact of CanAssist Breast on Physician’s Decision About the Use of Adjuvant Chemotherapy in Early Breast Cancer. Cureus (December 2024 – Note: Future date as per source)
- Risk Stratification of Early Breast Cancer (HR +/HER 2–) by CanAssist Breast and Its Corelation with Other Online Prognostic Tools: Experience from a Single Center. Indian Journal of Medical and Paediatric Oncology (August 2023)
- Impact of cost of Oncotype DX versus CanAssist Breast, an Indian prognostic test, in the management of node-negative early breast cancer in a single centre in India. JCO Global Oncology (August 2023)
- Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method. BMC Cancer (July 2023)
- The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective. Indian Journal of Medical and Paediatric Oncology (November 2022)
- A prospective single arm study evaluating the outcome of neoadjuvant chemotherapy in locally advanced/border line resectable gall bladder cancer. Annals of Oncology (November 2022)
- A single centre study from western India to evaluate the frequency of developing second and subsequent multiple primary malignancies among cancer survivors. Surgical and Experimental Pathology (September 2022)
- An Investigator-Initiated Study of Gemcitabine and Capecitabine in Indian Patients with Unresectable or Metastatic Gallbladder Cancer. Oncology Journal of India (May 2022)
- Outcome in patients of hormone receptor (HR) positive (Her 2) negative metastatic breast cancer treated with palbociclib – A real-world experience. International Journal of Molecular and Immuno Oncology (January 2022)
Consultation Fees & Treatment Costs
| Treatment Type | Estimated Cost (INR) | Estimated Cost (USD) |
| Chemotherapy (per cycle) | ₹ 30,000 – ₹ 1,50,000+ | $ 360 – $ 1,800+ |
| Immunotherapy (per cycle) | ₹ 1,50,000 – ₹ 4,00,000+ | $ 1,800 – $ 4,800+ |
| Targeted Therapy (monthly cost) | ₹ 50,000 – ₹ 3,00,000+ | $ 600 – $ 3,600+ |
International Patient Assistance
- Language Support: Dr. Bapna is fluent in English, Hindi, and Rajasthani. Cancer Rounds can assist in arranging interpreter services for other languages if needed by international patients.
- Visa & Travel Assistance: Cancer Rounds supports international patients with medical visa facilitation, travel planning, airport transfers, and identifying suitable accommodation options..
- Pre-treatment Virtual Consultations: Cancer Rounds can help coordinate remote second opinions or initial virtual consultations with Dr. Ajay Bapna, allowing international patients to discuss their case and treatment options before travelling to India.
Patient Success Stories & Testimonials
Treatment Approach & Philosophy
- Patient-Centred Care: Dr. Bapna is known for his focus on accurate diagnosis and providing empathetic treatment. He tailors care plans to individual patient needs, ensuring clarity and support throughout the treatment process. He is fluent in English, Hindi, and Rajasthani, facilitating effective communication.
- Technology & Innovation: Dr. Bapna actively incorporates modern advancements in medical oncology, including Immunotherapy and Targeted Therapy, alongside traditional Chemotherapy. His membership in international societies like ASCO and his research involvement reflect his commitment to evidence-based medicine and utilising innovative approaches for better patient outcomes.














